Mometasone Furoate Cipla (Mometasone Furoate)

Mometasone furoate is an inhaled corticosteroid that targets airway inflammation in chronic respiratory disorders.

• Asthma: provides maintenance therapy to reduce exacerbations and improve lung function.
• Chronic obstructive pulmonary disease (COPD): used as an adjunct to bronchodilators to improve symptoms and decrease flare‑ups.
• Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

• Mometasone furoate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses pro‑inflammatory cytokine production, reduces eosinophil recruitment, and stabilises mast cells, leading to decreased airway inflammation and hyper‑responsiveness.

Mometasone furoate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Oral thrush (candidiasis): localized fungal infection in the mouth.
• Hoarseness or dysphonia: voice changes due to laryngeal irritation.
• Cough or throat irritation: mild irritation after inhalation.
• Headache: transient discomfort.
• Dry mouth: reduced salivary flow.
• Nasal congestion: mild nasal blockage.

Serious or Rare Side Effects

• Adrenal suppression: reduced endogenous cortisol production.
• Pneumonia: increased risk of lower respiratory infection.
• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Immunosuppression: heightened susceptibility to infections.
• Paradoxical bronchospasm: sudden worsening of airway obstruction.
• Osteoporosis with long‑term use: decreased bone mineral density.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications.

• Infection risk: assess for active respiratory infections before use.
• Growth monitoring: regularly check growth velocity in children.
• Discontinuation: taper gradually to avoid adrenal insufficiency.
• Administration technique: use a spacer device and rinse mouth after inhalation to reduce local effects.
• Oral candidiasis: monitor for signs of fungal infection and treat promptly if present.
• Store at ambient temperature: keep in original container, protect from moisture and heat.

Mometasone furoate can interact with other medicines that affect corticosteroid metabolism or immune function.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure.
• Systemic corticosteroids: additive risk of adrenal suppression.
• Ritonavir (HIV protease inhibitor): can raise mometasone levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy.
• Diuretics (e.g., furosemide): risk of hypokalaemia may be enhanced.
• Beta‑agonists: possible reduction in bronchodilator response.
• Antifungal azoles (e.g., fluconazole): may modestly increase exposure.